.
Science Daily : Hormone Disorders
Hormone Disorders News -- ScienceDaily
Read the latest research on endocrinology. Learn about hormone disorders, new hormone treatment options, hormone therapy and more.

ScienceDailyHormone Disorders News
  • Hormone therapy linked to lower non-Hodgkin lymphoma risk
    Menopausal hormone therapy use is linked to a lower risk of B-cell non-Hodgkin lymphoma, research has found. "The connection between lymphomas and menopausal hormone therapy use hinges on understanding the disease's biology and the window of susceptibility," the lead researcher said. "Hormone therapy is of interest because the loss of estrogen coupled with aging in women result in decreased immune function, which can elevate risk of non-Hodgkin lymphoma."

  • Hormones in action: It's all about the right partner
    Thousands of regulatory regions on the genomic DNA determine which part of a cell’s genetic information is expressed and which is silent. Researchers analyzed such control-regions and the changes in activity that follow treatment with a hormone. They showed that -- depending on the cell type -- a single hormone can influence different regions.

  • Childhood abuse may impair weight-regulating hormones
    Childhood abuse or neglect can lead to long-term hormone impairment that raises the risk of developing obesity, diabetes or other metabolic disorders in adulthood, according to a new study. The study examined levels of the weight-regulating hormones leptin, adiponectin and irisin in the blood of adults who endured physical, emotional or sexual abuse or neglect as children. The study found dysregulation of certain hormones in people who had been abused or neglected as children.

  • Genetic testing may improve selection of women with ER-positive breast cancer for 10 rather than five years of hormonal therapy
    Genetic analyses of results from 1125 postmenopausal women being treated for estrogen responsive breast cancer have shown that some of them are more likely than others to have a late recurrence of their cancer and might benefit from ten years of hormone therapy rather than five. The findings are the latest to come from the ATAC trial, a double-blinded phase III clinical trial that randomly assigned postmenopausal women with early, estrogen receptor positive (ER+) breast cancer to receive the hormone therapies anastrozole or tamoxifen, or a combination of the two.

  • Estradiol preserves key brain regions in postmenopausal women at risk for dementia
    When initiated soon after menopause, hormone therapy with estradiol prevented degeneration in key brain regions of women who were at heightened dementia risk, according to a new study. The investigators also found that another type of hormone therapy, marketed under the brand name Premarin, was far less protective. Premarin is a mixture of 30-plus substances derived from the urine of pregnant mares. Estradiol -- the dominant sex-steroid hormone in woman -- accounts for about 17 percent of Premarin's total content. Other Premarin components exert various endocrinological effects on different tissues.

The Canary Club is an educational advisory group with a team of medical advisors headed by Richard Shames, M.D.